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ABSTRACT 
Alzheimer’s disease is the most prevalent form of dementia and is 
characterized by the presence of beta-amyloid plaques and tau tangles. Thioflavin-T, a 
fluorescent molecule, is known to have a high binding affinity to beta-amyloid. The 
high binding association is optimal for use as an affinity tag in the synthesis of 
targeted molecular imaging probes for detection by hyperpolarized 129 Xe MRI. An 
effort to move away from gadolinium-based contrasts for MRI is at the forefront of 
research due to evidence of toxic gadolinium build up in numerous organs. The goal of 
this project was to synthesize six Thioflavin-T analogues that could have greater 
binding associations and potentially be used to construct xenon probes. The six 
analogues were synthesized.   
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CHAPTER 1 
 
INTRODUCTION 
 
Alzheimer’s disease (AD) is the most common form of dementia and the most 
prevalent neurodegenerative disease.1,2 Dementia is a disease of aging and greatly 
affects the geriatric population of 65 and older.3 Of this elderly population 11% are 
AD patients.3 Aside from aging, risk factors for AD include gender, low education 
levels, smoking, heart disease, stroke, high blood pressure, diabetes, obesity, and 
concussions resulting in loss of consciousness specifically for men.4,5 While AD 
cannot be definitively diagnosed until post mortem, criteria for a clinical diagnosis 
includes cognitive decline in memory, reasoning, visuospatial skills, and language, 
and changes in personality and behavior.6,7 Clinicians also use imaging techniques 
such as PET, CT and MRI scans to rule out other etiologies when a patient reports a 
complaint of cognitive decline.3  
    The pathophysiological hallmarks of AD are beta-amyloid plaques, 
neurofibrillary tau tangles, and neuronal atrophy.8 While, AD has a number of 
histopathological factors, beta-amyloid plaques are the focus of this thesis. Amyloid 
fibrils are characterized as insoluble protein materials.9 They are a hallmark of chronic 
and neurodegenerative diseases beyond AD; which include Parkinson’s disease and 
type II diabetes.10-13 Beta amyloid has been shown to be involved in triggering 
synaptic dysfunction, regiospecific neuronal death, and loss of neural connectivity.14 
Amyloid plaques are made of 39 to 43 amino acid peptide sequences of the amyloid 
 2 
 
beta (Aβ) protein.15 Aβ is a section of the amyloid precursor protein (APP).15 The Aβ 
peptide is found in two locations on APP: the C-terminus of the extracellular domain 
and the transmembrane domain.15  The production of Aβ requires multiple proteases: 
α-secretase, β-secretase, and γ-secretase.15 α-secretase severs APP in the middle which 
halts the production of Aβ that would result in disease onset. β-secretase slices APP at 
the N terminus of Aβ and γ-secretase cuts APP at the C terminus.15 γ-secretase is 
essential for a number of cell signaling cascades.15 γ-secretase produces Aβ of varying 
lengths with the prominent being 40 and 42 amino acids.15 Due to the greater number 
of hydrophobic residues, Aβ42 has a statistically higher chance of aggregation than 
Aβ40. 
    Thioflavin T (ThT) (Figure 1) is a fluorescent molecule and is the gold 
standard for staining and identifying beta-amyloid fibrils which dates back to the late 
1950’s.16   ThT binds to the divots along the surface of the fibrils.16 Upon binding to 
the fibrils, the ThT fluorescence intensity signal dramatically increases.9  
 
Figure 1: Structure of ThT 
The increase in the fluorescence intensity is due to the lack of rotation between 
carbon-carbon bond between the benzylamine and benzothiole rings.9, 10, 16 The 
restriction in rotation maintains the excitation since unbound ThT has a low energy 
threshold and thus free rotation which dampens the excited states from photon 
excitation.9 Although ThT has a high affinity to beta amyloid, many groups have 
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synthesized ThT analogues with comparable association constants such as Jung et al.2  
The best association constants of the Jung group are 3.27 µM, 6.03 µM, and 7.33 µM.2  
  
   
Figure 2: Anatomy of Xe biosensor  
The importance of ThT in the greater application of this thesis is to be used in 
conjunction with supramolecular complexes and Hyperpolarized (HP) xenon (Xe) 
magnetic resonance imaging (MRI).  Supramolecular complexes (Figure 2, provided 
by lab mate A. Fernando) such as rotaxanes, pillararenes, and cyclodextrin are all cage 
molecules that have the potential to serve as Xe probes by forming binary or ternary 
complexes by encapsulating the noble gas.17 The xenon-129 molecular probe would 
contain a linker joining the molecular cage with the targeting molecule.17 We envision 
that ThT would be an excellent small molecule for targeting beta-amyloid. In the case 
of a rotaxane probe an alkyl chain linker would be threaded through a macrocyclic 
cage, where it would be able to participate in non-covalent bonding with the host’s 
cavity, creating a pocket to capture Xe.17 The xenon that is encapsulated could then be 
selectively detected using a modified MRI instrument. 
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    Magnetic resonance imaging (MRI) is the medicinal application of Nuclear 
Magnetic Resonance (NMR). MRI is an imaging technique that permits excellent 
spatial and temporal images of anatomy without the use of radiation.18 MRIs are able 
to image the body through the use of magnetic fields, typically detecting the protons in 
water contained in all tissues of the body.18 The magnetic field applied by the MRI 
instrument forces the magnetic moments of the protons in the tissues to align with the 
applied field, and when a radiofrequency is discharged to the body it causes the 
protons to misalign.18 Once the radiofrequency is terminated the protons return to the 
magnetic influenced orientation which releases energy and produces a signal that can 
be converted into three-dimensional images.18  
MRI data that have been acquired with the assistance of molecular contrast agents 
often provide sharper images, leading to better clinical application. Contrast agents 
improve imaging by altering the relaxation times of the protons, which in turn 
heightens contrast in the images.18 The most widely used contrasting agents are 
gadolinium-based and have been medicinally used for over 30 years.19 The initial 
safety profile of the gadolinium agents were not alarming apart from patients with 
renal failure who would develop nephrogenic systemic fibrosis upon contrast agent 
exposure.19 However, as gadolinium contrasting agents continued to be used in 
diagnostic MRI, adverse effects and toxicity have been reported, and warnings and 
restrictions by the U.S Federal Drug Administration and European Medicines Agency 
have been issued.20, 21 Gadolinium-based contrasting agents (GBCAs) (Figure 3) are 
divided by their chemical structures and properties as linear or macrocyclic and ionic 
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or non-ionic.19 The stability of the gadolinium complex from most to least are 
macrocyclic, ionic linear, and non-ionic linear.19  
 
Figure 3: Structures of Gd contrast agents  
The stability of the GBCAs is determined based on how well the complex is able 
to keep the Gd3+ ion in its cavity.19 Retaining the Gd3+ ion is crucial because it is a 
toxic heavy metal. In recent years data has been presented that has rejected the safety 
of GBCAs. It was hypothesized that the GBCAs were excreted from the body through 
the kidneys in healthy patients; however, gadolinium has been shown to accumulate in 
the tissue of patients who have gone through contrast MRI.22 Studies have shown that 
Gd accumulates in the denate nucleus and globus pallidus of the brain, bone, skin, and 
liver.22 Regardless of renal function Gd build-up is bound to occur, which is alarming 
due to the toxic effects.  
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    Due to the safety concerns of gadolinium it is important to develop safer 
alternatives. A promising alternative is HP 129Xe MRI. HP 129Xe MRI has high 
efficacy in imaging and is safe.23 Xe has already been used safely as a contrast media 
for lung imaging via computed tomography (CT).24 While non-hyperpolarized xenon 
produces a low intensity magnetic resonance signal, the process of hyperpolarizing 
xenon uses polarized lasers to specifically excite the electrons of gaseous rubidium in 
the presence of a magnetic field.23 When these excited atoms collide with xenon-129 
atoms, they transfer their electron spin polarization to the nucleus of the xenon atom, 
resulting in xenon having up to 75% of their magnetic spins aligned with the external 
magnetic field.33 This technique, when combined with a MRI pulse sequence called 
HyperCEST, increases the sensitivity of xenon-129 magnetic resonance signal a 
billion fold, creating a molecular imaging technique that, in principle, has comparable 
sensitivity to the state of the art technologies, such as positron emission tomography 
(PET).17 Hyperpolarized Xe atoms when introduced into the human body do not 
provide targeted imaging, so a supramolecular complex with an affinity tag is 
necessary for regiospecific images to be produced. The purpose of this study was to 
synthesize six ThT analogues that could potentially be used as the affinity tag in 
various supramolecular complexes needed for HP 129Xe MRI. The following chapter 
describes the synthesis of these tags and presents a possible scheme for attaching them 
to supramolecular hosts.  
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CHAPTER 2 
 
METHODS AND DISCUSSION 
 
 Thioflavin is a dye with a backbone composed of benzothiazole and 
aminobenzoyl rings.12, 25 The synthesis of the majority of ThT analogues (Figure 4) 
required the use of high temperatures, acidic solvents, cyclic benzoic acids, amino 
groups, and lengthy reaction durations.  
 
 
   
Figure 4: ThT analogues synthesized 
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Analogue R X R’ Yield 
4 Intermediate H S NH2 74% 
3 OCH3 S NH2 34% 
2 H O NH2 69% 
1 OCH3 O NHCH3 0.08% 
 
Figure 5: General reaction conditions for ThT and yield 
 The synthesis of analogues 1, 2, 3, and 4 involved the condensation of the 
amino phenol / benzothiol and 4-aminobenzoic acid in polyphosphoric acid at high 
temperatures for 4 hours. (Figure 5) Analogue 4 was completed by monomethylating 
the product of the condensation of the respective phenol and benzoic acid reagents via 
reductive amination. The terminal amine was deprotonated by sodium methoxide, 
reacted with paraformaldehyde and then reduced with sodium borohydride, in the 
polar protic solvent methanol. 
 The low yield of analogue 1 is due to the methoxy being electron donating. 
The electron donation makes the 4-amino-2-methoxybenzoic acid a poor electrophile.  
The yield of analogue 3 is much better than analogue 1 even though the same benzoic 
acid is used because sulfur is a far better nucleophile than oxygen.  
 Analogue 1 was a difficult synthesis resulting in a 0.08% yield of product. The 
procedure followed was that of Jung et al.2 After careful inspection of 1H, 13C, and 2-
D NMR spectra, we concluded that the desired product, which contained a methoxy 
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group, was not synthesized by myself or Jung. Jung reported chemical shifts for the 
methoxy in the 1H and 13C NMR as 2.90 and 30.26; respectively. Both shifts are more 
upfield than expected. In 1H and 13C NMR a methoxy shift is expected to be in the 
range of 3.3 – 3.8 ppm and 40 – 60 ppm; respectively. The amine protons were not 
reported by Jung, which were extremely useful in the determination of the product’s 
structure. The amine protons were at two very different chemical shifts in the 1H 
NMR. One amine proton was observed at 4.18 ppm and the other at 11.54 ppm. Both 
amine protons integrated to 1, which suggested that the protons were in two different 
environments. After careful and methodical investigation, it was proposed that the 
product synthesized was a N-substituted amine with a hydroxyl group on the aniline 
and not the respective methoxy meta-substitution on the aniline (Figure 6). 
 
 
 
Figure 6: Structure of Analogue 1. A was the synthesized product. B was the expected 
product.  
 It is proposed that in the presence of PPA and at high temperatures, the oxygen 
of the methoxy on the starting reagent, 4-amino-2-methoxybenzoic acid, is protonated. 
The methyl group is now the leaving group which is then picked up by the amine of 
another mole of benzoic acid. 
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Figure 7: Mechanism of ThT analogues 2,3 and 4 
The mechanism of 2,3 and 4 (Figure 6) for ThT formation begins with the 
protonation of the carbonyl oxygen followed by the nucleophilic addition of the amine 
of the phenol / benzothiol to the carbonyl. The next step is a loss of water by the 
hydroxyl group picking up a proton by the adjacent amine. The oxygen / sulfur then 
attacks the reduced carbonyl C to form the benzo-oxazole / thiazole ring. The next step 
is a second condensation where water is lost by the remaining hydroxyl group picking 
up a proton. The final step is the deprotonation of the amine. 
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Figure 8: Synthesis of analogues 5 and 6 
The synthesis of analogue 5 (Figure 7) was the condensation of 4-
dimethylaminobenzoaldehyde and 2-amino-6-methoxybenzothiazole in anhydrous 2-
propanol with a catalytic amount of acetic acid for 18 hours. The one pot synthesis of 
analogue 6 (Figure 7) was the condensation of 4-dimethylaminobenzoaldehyde and 2- 
aminothiophenol in DMSO for 2 hours. 
 
 12 
 
 
Figure 9: Mechanism of analogue 5  
The mechanism of 5 begins with the nucleophilic addition of the amine to the 
carbonyl. The base then deprotonates the amine as the oxygen acting as a Bronsted 
base picks up a proton from water. This happens twice. Finally, to form a double bond 
an E1  reaction occurs, water is eliminated as the by-product which results in a 
carbocation. The extra pair of electrons on nitrogen are then donated to create a double 
bond with the carbon. 
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The ThT analogues 1-6 were synthesized.  Prior to coupling these ThT analogs to 
the supramolecular complexes to be used in conjunction with HP 129 Xe MRI, binding 
studies between the analogs and beta-amyloid fibrils should be done to determine the 
association constant for each analogue.  The binding studies would require the 
formation of beta-amyloid fibrils, which are synthesized through nucleation and 
growth phases.28 The fibrils are formed in low pH aqueous solutions at 37 oC with 
agitation.29 The development of the protein aggregates can be assessed by small angle 
light scattering (SALS) and light transmittance measurements.30 The fluorescence of 
ThT allows for the binding association constants of the analogs to be determined with 
the use of a spectrofluorophotometer.31 The excitation wavelength for each ThT 
analogue will vary which requires for individual measurements obtained from a UV-
VIS spectrophotometer.  The literature value of the excitation wavelength for the 
standard ThT molecule is 440 nm.32  
The binding studies will give insight on the potential efficacy of the ThT 
analogues conjugated to the supramolecular complexes used in HP 129 Xe MRI. The 
greater the association constant, the greater the affinity the ThT analogues have 
towards beta amyloid fibrils.  
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Figure 10: Synthesis of Rotaxane-ThT probe 
 After synthesizing the ThT analogues and conducting the binding studies to 
determine the association constants, the following step is the synthesis of the Xe 
biosensor.  The synthesis of the biosensor, completed by lab mate Ashvin Fernando,  
(Figure 9, provided by A. Fernando) begins with the acylation of a ThT analogue with 
a 6-carbon alkyl acyl chloride chain to form an amide bond. Following the acylation, 
the ThT complex undergoes a SN2  reaction with furan protected malemide. Finally, in 
a one pot, high temperature environment, the malemide complex and the cyclodextrin 
cage along with an anthracene linker are combined.  The anthracene and malemide 
undergo a Diels-Alder reaction; and, the cyclodextrin does a self-inclusion with the 
affinity tag and linker complex to become an interlocked molecule. 
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Experimental  
The following protocols were used to synthesize all known compounds.  
Reagents and Solvents 
The following reagents and solvents were used: 4-amino-2-methoxybenzoic acid, 2-
aminophenol, polyphosphoric acid, sodium carbonate, sodium sulfate, ethyl acetate, 
sodium methoxide, paraformaldehyde, methanol, sodium borohydride, 4-
dimethylaminobenzaldehyde, 2-aminothiophenol, dimethyl sulfoxide, 4-aminobenzoic 
acid, 2-aminothiophenol, sodium hydroxide, acetic acid, 2-propanol, and deuterated 
chloroform. 
All reagents and solvents were purchased from Fisher Scientific, Sigma Aldrich, and 
Cambridge Isotopes Laboratories.  All materials with the exception of 2-propanol 
were used without alteration. 2-propanol was dried with 3 Å molecular sieves for 48 
hours before use.  
Instrumentation  
1H and 13C NMR spectra were acquired from either a Bruker Avance 300 MHz 
spectrometer or Bruker Avance 400 MHz spectrometer. Flash column chromatography 
was completed using Teledyne ISCO CombiFlash Rf with Redisep silica cartridges.  
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Synthesis of 2-(benzo[d]oxazol-2-yl)-5-(methylamino)phenol, 1 
 
 
 
    2-aminophenol (0.57 g, 5 mmol), 4-amino-2-methoxybenzoic acid (0.83 g, 5mmol) 
and polyphosphoric acid were heated for 4 hours at 200℃. The reaction mixture 
cooled overnight. After, 10% sodium carbonate (100 mL) was poured into the mixture. 
An extraction was done using ethyl acetate which was then washed with brine and 
dried over sodium sulfate. The crude product was purified using column 
chromatography and the product was obtained (0.010 g, 0.08%).  NMR data was 
consistent with reported values.2 
1H NMR (300 MHz, CDCl3) δ 11.54 (s, 1H), 7.78 (d, J = 9.2 Hz, 1H), 7.63 (dd, J = 
6.9, 2.3 Hz, 1H), 7.53 (dd, J = 7.0, 2.3 Hz, 1H), 7.35 – 7.27 (m, 2H), 6.26 (s, 1H), 6.23 
(d, J = 2.3 Hz, 1H), 4.18 (s, 1H), 2.90 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 163.69, 160.60, 153.65, 148.74, 140.36, 128.04, 
124.35, 123.87, 118.12, 109.97, 105.55, 99.94, 97.88, 30.01. 
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Spectrum 1- 1H NMR of Analogue 1  
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Spectrum 2 – 13C NMR of Analogue 1 
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Synthesis of 4-(benzo[d]oxazol-2-41) aniline, 2 
 
 
 
4-aminobenzoic acid (0.83 g, 6 mmol), 2-aminophenol (0.54 g, 5 mmol), and 
polyphosphoric acid (20 g) were heated for 4 hours at 200℃. The reaction mixture 
cooled overnight. The mixture was then poured into 10% sodium carbonate (100 mL) 
and extracted with ethyl acetate. The extraction was concentrated, and the product was 
obtained by recrystallization with methanol and water (0.730 g, 69%).  
1H NMR (400 MHz, CDCl3) δ 8.06 (d, J = 8.7 Hz, 2H), 7.71 (dd, J = 6.6, 2.6 Hz, 
1H), 7.52 (dd, J = 6.7, 2.5 Hz, 1H), 7.34 – 7.27 (m, 2H), 6.76 (d, J = 8.7 Hz, 2H), 4.05 
(s, 2H). 
13C NMR (101 MHz, CDCl3) δ 163.90, 150.66, 149.81, 142.43, 129.57, 124.42, 
124.36, 119.43, 117.01, 114.81, 110.36. 
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Spectrum 3- 1H NMR of Analogue 2 
 21 
 
 
Spectrum 4- 13C NMR of Analogue 2 
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Synthesis of 2-(2’ methoxy -4’-aminophenyl) benzothiazole, 3 
 
 
2-aminothiophenol (0.58 g, 5 mmol), 4-amino -2-methoxybenzoic acid (0.83 g, 5 
mmol), and polyphosphoric acid (8.2 g) were heated for 4 hours at 100℃. The mixture 
was cooled overnight. After, the mixture was poured into water and a precipitate was 
observed. Sodium hydroxide pellets were added until the pH was 7. The precipitate 
was filtered, and the product was obtained (0.44 g, 34%). NMR data was consistent 
with reported values.2 
1H NMR (300 MHz, CDCl3) δ 8.32 (d, J = 8.5 Hz, 1H), 8.00 (d, J = 7.6 Hz, 0H), 7.87 
(d, J = 7.2 Hz, 1H), 7.44 (ddd, J = 8.2, 7.2, 1.3 Hz, 1H), 7.30 (ddd, J = 8.2, 7.2, 1.2 
Hz, 1H), 6.42 (dd, J = 8.5, 2.2 Hz, 1H), 6.31 (d, J = 2.1 Hz, 1H), 4.00 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 163.94, 158.98, 152.42, 150.42, 135.65, 131.08, 
125.76, 123.90, 122.14, 121.14, 113.26, 108.09, 97.64, 55.63. 
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Spectrum 5- 1H NMR of Analogue 3  
 24 
 
Spectrum 6- 13 C NMR of Analogue 3 
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Synthesis of 2-(4-methylaminophenyl) benzothiazole, 4 
 
2-aminothiophenol (2.5 g, 20 mmol), 4-aminobenzoic acid (2.8 g, 20 mmol) and 
polyphosphoric acid (20 g) were heated for 4 hours at 200℃. The mixture cooled 
overnight. The mixture was then poured into sodium carbonate and the precipitate was 
filtered. The solid was purified by recrystallization with methanol and water (3.35 g, 
74%). 
1H NMR (400 MHz, CDCl3) δ 8.00 (d, J = 8.1 Hz, 1H), 7.91 (dt, J = 8.6, 2.0 Hz, 2H), 
7.85 (d, J = 7.6 Hz, 1H), 7.45 (ddd, J = 8.3, 7.2, 1.3 Hz, 1H), 7.32 (ddd, J = 8.3, 7.2, 
1.2 Hz, 1H), 6.74 (dt, J = 8.6, 2.0 Hz, 2H), 4.04 (s, 2H). 
13C NMR (101 MHz, CDCl3) δ 168.67, 154.31, 149.40, 134.68, 129.32, 126.23, 
124.62, 124.05, 122.62, 121.56, 114.93. 
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 After, the purified solid (0.24 g, 1 mmol) was dissolved in methanol (20 mL); and, 
sodium methoxide (0.054 g, 1 mmol) and paraformaldehyde (0.026 g, 1 mmol) were 
added to the solution. The reaction mixture was refluxed for 2 hours. Once complete 
the reaction mixture was cooled to 0℃ and sodium borohydride (0.038 g, 1 mmol) 
was added slowly. The mixture was refluxed for 1 hour, poured into 0℃ water, and 
then extracted with ethyl acetate. The extracts were dried over sodium sulfate and 
filtered. The product was obtained by chromatography (0.028 g, 11%).  
1H NMR (300 MHz, CDCl3) δ 8.02 (d, J = 8.1 Hz, 1H), 7.96 (d, J = 8.7 Hz, 2H), 7.84 
(d, J = 7.9 Hz, 1H), 7.45 (ddd, J = 8.3, 7.2, 1.3 Hz, 1H), 7.32 (ddd, J = 8.3, 7.3, 1.2 
Hz, 1H), 6.66 (d, J = 8.7 Hz, 2H), 2.92 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.09, 151.89, 129.43, 129.37, 126.32, 124.57, 
122.29, 121.53, 114.94, 112.23, 30.48. 
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Spectrum 7- 1H NMR of Analogue 4 Intermediate  
 28 
 
 
Spectrum 8- 13C NMR of Analogue 4 Intermediate  
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Spectrum 9- 1H NMR of Analogue 4  
 30 
 
 
Spectrum 10- 13C NMR of Analogue 4   
 31 
 
Synthesis of N-[[ 4-(Dimethylamino) phenyl] methylene]-6-methoxy-2– 
benzothiazoleamine, 5 
 
 
 
 
2-amino-6-methoxybenzothiazole (0.36 g, 2 mmol), 4-dimethylaminobenzaldehyde 
(0.30 g, 2 mmol) and anhydrous 2-propanol (20 mL) were added to a flask. Acetic 
acid (0.11 mL) was added dropwise to the reaction and it was refluxed for 18 hours. It 
was then allowed to cool to room temperature and the product was obtained through 
filtration (0.441 g, 71%). NMR data was consistent with reported values.27 
1H NMR (400 MHz, CDCl3) δ 8.81 (s, 1H), 7.90 (d, J = 8.4 Hz, 2H), 7.81 (d, J = 8.9 
Hz, 1H), 7.27 (d, J = 2.6 Hz, 1H), 7.03 (dd, J = 8.9, 2.6 Hz, 1H), 6.73 (d, J = 9.0 Hz, 
2H), 3.88 (s, 3H), 3.11 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 170.83, 164.73, 157.38, 153.82, 146.45, 135.34, 
132.51, 123.22, 122.80, 115.16, 111.66, 104.75, 55.95, 40.26. 
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Spectrum 11- 1H NMR of Analogue 5 
 33 
 
 
Spectrum 12- 13C NMR of Analogue 5 
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Synthesis of 2-( 4- Dimethylaminophenyl) benzothiazole, 6 
 
 
 
4 – dimethylaminobenzaldehyde (0.75 g, 5mmol), 2- aminothiophenol (0.69 g, 6 
mmol) and DMSO (10 mL) were put in a flask and refluxed for 2 hours. The reaction 
mixture was then left to cool to room temperature. Once at room temperature water 
was added to the mixture and the precipitate was separated by filtration. A 
recrystallization with methanol and water produced the final product (0.805 g, 63%). 
NMR data was consistent with reported values.26 
1H NMR (300 MHz, CDCl3) δ 8.04 – 7.88 (m, 3H), 7.84 (d, J = 7.8 Hz, 1H), 7.44 
(ddd, J = 8.3, 7.3, 1.3 Hz, 1H), 7.30 (ddd, 8.3, 7.3, 1.3 Hz, 1H), 6.75 (d, J = 9.0 Hz, 
2H), 3.06 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 168.94, 154.53, 152.32, 134.67, 129.01, 126.11, 
124.32, 122.41, 121.52, 121.48, 111.83, 40.33. 
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Spectrum 13- 1H NMR of Analogue 6 
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Spectrum 14 – 13C NMR of Analogue 6 
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